Cargando…
P1389: RUXOLITINIB DEMONSTRATES A GREATER CORTICOSTEROID-SPARING EFFECT THAN BEST AVAILABLE THERAPY IN PATIENTS WITH CORTICOSTEROID-REFRACTORY/DEPENDENT CHRONIC GRAFT-VS-HOST DISEASE
Autores principales: | Zeiser, R., Russo, D., Ram, R., Hashmi, S., Chakraverty, R., Moritz Middeke, J., Giebel, S., Sarkar, R., Gowda, M., Gunes, S., Stefanelli, T., Lee, S. J., Teshima, T., Locatelli, F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429566/ http://dx.doi.org/10.1097/01.HS9.0000848416.66197.62 |
Ejemplares similares
-
Corticosteroid-sparing therapy: practice patterns among uveitis specialists
por: Esterberg, Elizabeth, et al.
Publicado: (2011) -
1389. Nontuberculous Mycobacterial Infections of the Upper Extremity
por: Polveroni, Thomas M, et al.
Publicado: (2021) -
Corticosteroid-Sparing Effect of Chromoglycate Sodium and Nedocromil
por: Capristo, A. F., et al.
Publicado: (1994) -
Long‐Term Corticosteroid‐Sparing Immunosuppression for Cardiac Sarcoidosis
por: Rosenthal, David G., et al.
Publicado: (2019) -
Finding the Best: Corticosteroids for the Treatment of West Syndrome
por: Kannan, Lakshminarayanan, et al.
Publicado: (2022)